A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder
SH Kim, SY Huh, SJ Lee, AR Joung, HJ Kim - JAMA neurology, 2013 - jamanetwork.com
Importance A previous 2-year analysis of repeated rituximab treatment in patients with
neuromyelitis optica (NMO) revealed significant improvements in relapse rates and
disability. We report the findings from the longest follow-up of rituximab treatment in NMO,
which provide reassurance regarding the long-term efficacy and safety of rituximab in NMO.
Objective To report the results of rituximab treatment in patients with relapsing NMO or NMO
spectrum disorder (NMOSD) for a median of 60 months. Design, Setting, and Participants …
neuromyelitis optica (NMO) revealed significant improvements in relapse rates and
disability. We report the findings from the longest follow-up of rituximab treatment in NMO,
which provide reassurance regarding the long-term efficacy and safety of rituximab in NMO.
Objective To report the results of rituximab treatment in patients with relapsing NMO or NMO
spectrum disorder (NMOSD) for a median of 60 months. Design, Setting, and Participants …